David A. Siegel Acumen Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 499,100 shares of ABOS stock, worth $723,695. This represents 0.0% of its overall portfolio holdings.
Number of Shares
499,100
Previous 469,100
6.4%
Holding current value
$723,695
Previous $1.16 Million
26.23%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ABOS
# of Institutions
82Shares Held
41.5MCall Options Held
2.9KPut Options Held
761K-
Ra Capital Management, L.P. Boston, MA14.9MShares$21.7 Million0.42% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$4.95 Million2.23% of portfolio
-
Franklin Resources Inc San Mateo, CA3.27MShares$4.75 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$3.13 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.94MShares$2.81 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $58.7M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...